Kornimate/medical-research-clean huggingface dataset:
glucocorticoids with antihistamines versus antihistamines in acute urticaria in emergency

Conditions: Acute Urticaria

Summary: acute urticaria is common and affected 12% of population. 400 patients come in department emergency of toulouse each year and there aren't many studies in literature which evaluate the glucocorticoids treatment. the standard treatment of urticaria is antihistamines h1, but glucocorticoids treatment administered orally for short course would permit to increase quickly acute urticaria uncomplicated. clinical trial, prospective randomized double blinded of adults with acute urticaria less 24 hours duration and no take treatment urticaria before.

acute urticaria is common and affected 12% of population. 400 patients come in department emergency of toulouse each year and there aren't many studies in literature which evaluate the glucocorticoids treatment. acute urticaria is pruritic and incapacitating for daily life. the standard treatment of urticaria is antihistamines h1, but glucocorticoids treatment administered orally for short course would permit to increase quickly acute urticaria uncomplicated. clinical trial, prospective randomized double blinded of adults with acute urticaria less 24 hours duration and no take treatment urticaria before. one group randomized received 40mg of cortancyl and 1 pill of citerizine and another group randomized received 1 pill citerizine and placebo like cortancyl. pharmacy hospital takes care of randomization. pruritus evaluated with icth score and rash evaluated with nine rule of wallace, the patient is evaluated in t0, one hour after and contacted by telephone at j2, j5, j15, j 21 itch score, wallace extension, observance, side effects are asked him.

Eligibility criteria:
inclusion criteria: * adults * urticaria rash no more 24 h duration and no take treatment for urticaria exclusion criteria: * patients were presented severe anaphylaxis or taken antihistamines or glucocorticoids within 5 days of arrival at ed, * severe infection * pregnancy * patients bpco * diabetics * allergy corticosteroids * refusal to comply * participate an other study

Keywords: acute urticaria glucocorticoids antihistamines prurit itch score rash
perioperative rehabilitation in operation for lung cancer

Conditions: Lung Cancer; Non Small Cell Lung Cancer

Summary: background: improved surgical techniques combined with effective adjuvant chemotherapy, has led to a better survival in individuals with nsclc. the treatment of nsclc and other cancer diseases are after all still complex and potentially lethal. study aim: the rationale for the study proluca is to identify the optimal timing of exercise to improve recovery after surgery in patients operated for lunge cancer with focus on physical capacity and quality of life. who can participate? patients above 18 years and diagnosed with lung cancer and referred for operation. participation in this study is not possible if the participants by a doctor are advised not to do strenuous exercise. what does the study involve? the intervention consists of a combination of (1) exercise before surgery and (2) exercise after surgery for lung cancer. 1. exercise before surgery is a home-based exercise program is individually designed and must be performed for at least 30 minutes every day until surgery. the home-based exercise program varies in length due to number of days until surgery, and the intention is not exceed 14 days. 2. the exercise initiated two weeks and 6 weeks after surgery consists of a 12 weeks rehabilitation program and three individual counseling sessions. special needs in terms of smoking cessation, nutritional counseling or patient education, this is also offered. the exercise consists of individually prepared supervised strength - and fitness exercise in a team, two sessions of 60 minutes/week. what interventions will be compared? a home-based post-operative exercise program, combined with exercise initiated two weeks after surgery, will be compared with usual care (exercise initiated six weeks after surgery). will all participants receive the same treatment? by draw it is decided which of the 4 groups the participants will attend to in the study: * group 1: home-based exercise before surgery and rehabilitation initiated as early as two weeks after surgery * group 2: home-based exercise before surgery and rehabilitation initiated six weeks after surgery * group 3: rehabilitation initiated as early as two weeks after surgery * group 4: rehabilitation initiated six weeks after surgery (usual practice as control group) what are the possible benefits and risks of participating? there are no risks or side- effects of participating other than muscle soreness and exercise is beneficial when it comes to recover from an operation from lung cancer.


Eligibility criteria:
inclusion criteria: * performance status 0-2 (who) * living in the city of copenhagen or surrounding municipalities * ability to read and understand danish * approval by primary surgeon exclusion criteria: * presence of metastatic disease or surgical inoperability * diagnosis of lung cancer not verified by histological diagnosis * cardiac disease

Keywords: cancer rehabilitation exercise lung cancer nsclc
pivotal study of the intravenous blood glucose (ivbg) system, in-clinic setting

Conditions: Diabetes; Hyperglycemia

Summary: the purpose of this study is to evaluate safety and accuracy of the ivbg system (the "system") when used to track blood glucose in insulin treated subjects with diabetes mellitus in an in-clinic setting for up to 72 hours (per subject). reference blood glucose measurements will be collected across the entire reportable range of the system (e.g., 40 400 mg/dl) with adequate sampling at the upper and lower ends of this range. ivbg system accuracy will primarily be assessed relative to iso 15197 criteria (i.e., within ±15 mg/dl at ysi glucose levels \ 75 mg/dl).


Eligibility criteria:
inclusion criteria: 1. age 18 years or older; 2. willing to participate in one 72-hour in-clinic session during which up to 72 venous blood samples drawn for ysi measurement of glucose concentration (maximum sampling frequency of 4 per hour), a fingerstick blood glucose measurement will also be performed at the time of each ysi blood draw; 3. if instructed, be willing not to perform any activities that would result in submersion of the sensor/potentiostat in water or willing to wear a waterproof covering when submerging the sensor/potentiostat; 4. have been diagnosed with insulin-requiring diabetes mellitus and are on multiple daily injections (mdi) or continuous subcutaneous insulin infusion (csii) insulin therapy; 5. able to speak, read, and write english. exclusion criteria: 1. have skin conditions or existing (or planned) medical instrumentation and/or dressings that preclude wearing the ivbg sensor (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis, or surgical dressings at the proposed wear site); 2. are pregnant (as demonstrated by a positive pregnancy test within 72-hours of device insertion); 3. have a contraindication to placement of a dedicated peripheral iv line; 4. have a known history of heparin-induced thrombocytopenia; 5. current participation in another investigational study protocol (if a subject has recently completed participation in another drug study, the subject must have completed that study at least 30 days prior to being enrolled in this study); 6. have any condition that, in the opinion of the investigator, would interfere with their participation in the trial or pose an excessive risk to study staff handling venous blood samples (e.g., known history of hepatitis b or c).
study of procalcitonin (pct)-guided antibiotic use in severe sepsis patients without obvious infection

Conditions: Severe Sepsis

Summary: a recent study has demonstrated that in low respiratory infections, a strategy using prescription of antibiotics based on the pro-calcitonin level allows decreasing recourse to antibiotics by 47% without prognostic modification. the aim is to evaluate the impact on antibiotics consumption of an algorithm using procalcitonin level in patients exhibiting severe sepsis symptomatology but without clearly identified hosted germs or infectious centre. this multicenter study is a randomized prospective open study involving 9 icu departments in france, comparing two strategies on antibiotherapy treatment period one based on procalcitonin level(experimental group) the other on physician's appreciation(control group) 140 adult patients should be included with a severe sepsis symptomatology, whose infectious etiology has not been proven. the main non-inclusion criterium is: the presence of a pathogen agent or infectious centre clearly identified. the primary outcome is the rate of patients undergoing antibiotic treatment at d5. secondary outcomes: duration of the antibiotic treatment, mortality rate and duration in stay in intensive care ward and evolution of the sofa score between d0, d3 and d5. duration of patient enrollment is 30 days.


Eligibility criteria:
inclusion criteria: * hospitalized in resuscitation ward * severe sepsis symptomatology * at least 2 sirs criteria * no infectious etiology detected * at least one organ deficiency exclusion criteria: * the presence of a pathogen agent or infectious centre clearly identified * pregnancy * burned * patients with therapeutic limitation * recent surgery * secondary neutropenia

Keywords: safety procalcitonin pct sofa sepsis antibiotic strategy sirs severe sepsis without obvious infection
bone mineral density effects of zoledronate in postmenopausal women with breast cancer

Conditions: Breast Cancer

Summary: this is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (bmd) of postmenopausal women with breast cancer.

this is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (bmd) of postmenopausal women with breast cancer. an approved bisphosphonate, alendronate, is of benefit in patients with osteoporosis, however, this agent has a roughly 30% incidence of gastrointestinal symptoms and up to 50% of patients may take the drug improperly, compromising absorption and potentially efficacy. zoledronate is a heterocyclic imidazole third generation bisphosphonate, which is administered intravenously (iv) and has little toxicity. zoledronate is more potent than alendronate, and because of its route of administration it does not have the problems of poor oral bioavailability and non-compliance.

Eligibility criteria:
inclusion criteria: * postmenopausal women, stage iii or axillary node positive * currently disease free of breast cancer and other invasive malignancies at the time of registration * no concurrent use of bisphosphonates exclusion criteria: * metastatic disease

Keywords: bone mineral density postmenopausal women
inspiratory muscle training on diaphragm thickness, inspiratory muscle strength and shoulder pain in tennis player

Conditions: Shoulder Pain; Inspiratory Muscle Training

Summary: shoulder pain is one of the most common musculoskeletal conditions among athletes and sports enthusiasts who engage in overhead sports, and it can be highly disabling. since the shoulder is one of the joints with the greatest range of motion in the human body, it is important to seek strategies that address trunk stability comprehensively to achieve full and effective joint mobility. the central role of the diaphragm in trunk stabilization has been the subject of research for over 50 years, although the exact mechanisms are still not fully understood. the objective of this study is to assess the effects of inspiratory muscle training on diaphragm thickness, inspiratory muscle strength, and shoulder pain in adult tennis players with non-specific shoulder pain. this is a single-blind, randomized controlled clinical trial. the intervention will last for 8 weeks. patients with non-specific shoulder pain will be randomly assigned to one of two groups. the experimental group will undergo specific inspiratory muscle training, while the control group will receive no specific training intervention. measurements of diaphragm thickness, inspiratory muscle strength, and shoulder pain will be taken before and after the intervention.


Eligibility criteria:
inclusion criteria: * tennis player who suffered from inespecific shoulder pain * training at least two times per week * have experienced at least 1 episode of non-specific shoulder pain in the last month * a positive result on diagnostic tests performed: neer test and jobe test exclusion criteria: * having taken anti-inflammatories or muscle relaxants within the last 72 hours before the study * pregnancy * previous diagnosis of respiratory or neurological diseases * previous surgeries, fractures, and dislocations in the dominant shoulder * inability to follow instructions during the study * all those for whom measuring maximum inspiratory pressure is contraindicated: unstable angina, recent myocardial infarction (within 4 weeks of the event) or myocarditis, uncontrolled systemic hypertension, recent pneumothorax, post-lung biopsy surgery of less than one week, postoperative abdominal or genitourinary surgery of less than 6 months, and urinary incontinence
study comparing the effect on disease activity when reducing or discontinuing etanercept in subjects with ra

Conditions: Rheumatoid Arthritis

Summary: this study involves rheumatoid arthritis patients in regular clinical setting who are already on etanercept treatment and are in remission or in a low disease activity (lda) state, and is intended to identify parameters that can serve as guidance in clinical settings. this study will consider the clinical and radiographic course in subjects when etanercept treatment is tapered or discontinued, and analyze the subjects' experience of disease worsening and the predictive values of clinical parameters, serum biomarkers and imaging on the clinical and radiographic course in different treatment groups. the effect of re-treatment with etanercept at treatment failure will also be studied.


Eligibility criteria:
inclusion criteria: * subject has a current das28 equal to or less than 3.2. * subject is currently receiving treatment with etanercept, either 25 mg twice weekly or 50 mg once weekly, for a minimum of 14 months at baseline * subject is currently receiving oral, sc or intramuscular methotrexate once weekly, 7.5 mg/week to 25 mg/week and at a stable dose for a minimum of 4 months at baseline. exclusion criteria: * subject has earlier had an attempt of discontinuing etanercept for reasons of remission or low disease activity state. * subject has received any disease-modifying anti-rheumatic drug, other than methotrexate, within one month before baseline. * subject has had a dose of prednisone (or equivalent) \>7.5 mg/day or has received intra-articular, intravenous, intramuscular, or subcutaneous corticosteroid within one month of baseline.
outpatient management of primary spontaneous pneumothorax: pigtail catheter with unidirectional valve vs. exsufflation, randomized prospective study

Conditions: Pneumothorax, Spontaneous

Summary: the management of spontaneous large pneumothorax is not consensual. the current management involves the establishment of a fuhrman catheter and an outpatient monitoring in pneumology consultation. another alternative is widespread: simple exsufflation. however, no study has looked at the direct prospective comparison of these 2 treatments.


Eligibility criteria:
inclusion criteria: * episode of primary spontaneous pneumothorax wide according to the criteria exclusion criteria: -
a study of pirtobrutinib (loxo-305) versus bendamustine plus rituximab (br) in untreated patients with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the purpose of this study is to compare the efficacy and safety of pirtobrutinib (loxo-305; arm a) compared to br (arm b) in patients with cll/sll who have not been treated. participation could last up to five years.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cll/sll requiring therapy, per iwcll 2018 criteria * eastern cooperative oncology group (ecog) performance status 0-2 * adequate organ function * platelets greater than or equal to (≥)75 x 10⁹/liter (l) (≥50 × 10⁹/l for patients with evidence of bone marrow infiltrate), hemoglobin ≥8 grams/deciliter (g/dl), and absolute neutrophil count ≥0.75 x 10⁹/l * kidney function: estimated creatinine clearance ≥40 milliliters per minute (ml/min) exclusion criteria: * known or suspected richter's transformation at any time preceding enrollment * prior systemic therapy for cll/sll * presence of 17p deletion * central nervous system (cns) involvement * active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \[aiha\], idiopathic thrombocytopenic purpura \[itp\]) * significant cardiovascular disease * active hepatitis b or hepatitis c * active cytomegalovirus (cmv) infection * active uncontrolled systemic bacterial, viral, fungal, or parasitic infection * known human immunodeficiency virus (hiv) infection, regardless of cluster of differentiation 4 (cd4) count * concurrent use of investigational agent or anticancer therapy except hormonal therapy * patients requiring therapeutic anticoagulation with warfarin or another vitamin k antagonist * vaccination with a live vaccine within 28 days prior to randomization * patients with the following hypersensitivity: * known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib or bendamustine * prior significant hypersensitivity to rituximab

Keywords: btki btk inhibitor hematologic disease lymphoma, non-hodgkin's lymphoma, b-cell
mindful steps: promoting physical activity

Conditions: Copd; Heart Failure

Summary: this is a developmental project with two phases. the first phase will adapt an existing web-based intervention to incorporate mind-body exercises to develop a multi-modal intervention to promote physical activity in patients with copd and hf. the second phase will pilot test this new intervention in a longitudinal study (subjects randomized to intervention or usual care).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd or clinical diagnosis of hf syndrome (new york heart association class 1-3) * able to participate in an exercise program * have an active email account and access to a computer with internet connection exclusion criteria: * copd or hf exacerbation in the previous month * inability to ambulate * clinical signs of unstable cardiovascular disease * hypoxemia during 6mwt * inability to collect at least 7 of 14 days of baseline step counts * current participation in a cardiac or pulmonary rehabilitation program.
bmac enhanced coronary artery bypass grafting (cabg)

Conditions: Congestive Heart Failure

Summary: injection of concentrated bone marrow cells into the myocardium during cabg procedure.

injection of autologous concentrated bone marrow cells into the myocardium during cabg procedure.

Eligibility criteria:
inclusion criteria: subjects must meet all of the following inclusion criteria to be enrolled in the trial: * age 18 years and ability to understand the planned treatment. * patients with ischemic congestive heart failure requiring by pass surgery * congestive heart failure with ejection fraction 40%. * serum bilirubin, sgot and sgpt 2.5 time the upper level of normal. * serum creatinine \< 3.0 or no dialysis. * nyha performance status \> 3. * negative pregnancy test (in women with childbearing potential). * subject has read and signed the irb approved informed consent form * hematocrit ≥ 28.0%, white blood cell count ≤ 14,000, platelet count ≥ 50,000, creatinine ≤ 3.0 mg / dl, and/or no dialysis, inr ≤ 1.6 unless on coumadin, or ptt \<1.5 x control (to avoid bleeding complications) patients on coumadin will be corrected prior to the procedure and must have an inr\<1.6 at the time of randomization/surgery exclusion criteria: subjects will be excluded if they meet any of the exclusion criteria: * female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study. * history of prior radiation exposure for oncological treatment. * history of bone marrow disorder (especially nhl, mds) that prohibit transplantation. * history of abnormal bleeding or clotting. * history of liver cirrhosis. * acute myocardial infarction \< 4 weeks from treatment date. * known active malignancy or results outside of normal limits from the following tests: pap, chest x-ray, psa, mammogram, hemocult unless follow-up studies reveal patient to be cancer free. * active clinical infection being treated by antibiotics within one week of enrollment * terminal renal failure with existing dependence on dialysis * inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent. * unable to have 250cc bone marrow harvested. * medical risk that precludes anesthesia or asa class 5 * history of ventricular arrhythmia if aicd is not present. * history of ventricular aneurysm. * concurrent surgery such as cabg with valve surgery. * minimally invasive bypass surgery * life expectancy \<6 months due to concomitant illnesses * treatment with immunosuppressant drugs (including prednisone \> 5 mg per day) * patients undergoing urgent by pass surgical procedure * patients with hgb a1c \> 8.5%

Keywords: bone marrow concentrate cabg cardiac stem cell